FCGR3A and cancer: As clearly exhibited in Figure 3, FCGR3A mRNA expression was remarkably different in groups stratified by cancer type (recurrent patients) (p < 0.001), WHO grade (p=0.031), 1p19q codeletion (p < 0.001), and IDH1-mutation (p < 0.001), indicating the close correlation of FCGR3A mRNA expression with a series of significant clinical parameters.